Malla RR, Farran B, Nagaraju GP. Understanding the function of the tumor microenvironment, and compounds from marine organisms for breast cancer therapy. World J Biol Chem 2021; 12(2): 15-37 [PMID: 33815682 DOI: 10.4331/wjbc.v12.i2.15]
Corresponding Author of This Article
Ganji Purnachandra Nagaraju, DSc, PhD, Instructor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Atlanta, GA 30322, United States. email@example.com
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: All authors design, collect, wrote, and edit the paper.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ganji Purnachandra Nagaraju, DSc, PhD, Instructor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Atlanta, GA 30322, United States. firstname.lastname@example.org
Received: December 23, 2020 Peer-review started: December 23, 2020 First decision: January 11, 2021 Revised: January 13, 2021 Accepted: February 20, 2021 Article in press: February 20, 2021 Published online: March 27, 2021
The pathology and physiology of breast cancer (BC), including metastasis, and drug resistance, is driven by multiple signaling pathways in the tumor microenvironment (TME), which hamper antitumor immunity. Recently, long non-coding RNAs have been reported to mediate pathophysiological develop-ments such as metastasis as well as immune suppression within the TME. Given the complex biology of BC, novel personalized therapeutic strategies that address its diverse pathophysiologies are needed to improve clinical outcomes. In this review, we describe the advances in the biology of breast neoplasia, including cellular and molecular biology, heterogeneity, and TME. We review the role of novel molecules such as long non-coding RNAs in the pathophysiology of BC. Finally, we provide an up-to-date overview of anticancer compounds extracted from marine microorganisms, crustaceans, and fishes and their synergistic effects in combination with other anticancer drugs. Marine compounds are a new discipline of research in BC and offer a wide range of anti-cancer effects that could be harnessed to target the various pathways involved in BC development, thus assisting current therapeutic regimens.
Core Tip: Breast cancer (BC) is an aggressive and heterogenous disease. The BC tumor microenvironment contributes to immune evasion and chemoresistance in BC. Long non-coding RNAs contribute to BC pathophysiology and are potential BC biomarkers. Marine compounds display promising anticancer activity against BC. The use of novel bioengineering tools will enormously help in improving their production and clinical development for the treatment of BC and other cancers.
Citation: Malla RR, Farran B, Nagaraju GP. Understanding the function of the tumor microenvironment, and compounds from marine organisms for breast cancer therapy. World J Biol Chem 2021; 12(2): 15-37
According to GLOBOCAN (2018), 2.1 million females were diagnosed with breast cancer (BC) in 2018, accounting for 11.6 % of total cancer patients. As per this report, BC accounts for nearly 1 in 4 cancer cases among women, illustrating its high frequency. In fact, the incidence of BC ranks first among women-specific cancers worldwide. The elevated prevalence of BC compared to other cancers is due to its risk factors associated with menstruation, reproduction, intake of hormones, nutrition, and anthropometry, postponement of childbearing, etc. Additionally, the prevalence rate of BC increases in successive generations of high-risk populations due to inherited genetic predisposition.
The characterization of pathophysiology and treatment of BC is highly challenging due to its heterogeneous nature. BC displays rapid visceral as well as distant metastatic ability. Some BC subtypes can be highly aggressive and exhibit unique proliferation markers, endothelial growth factor receptor (EGFR) and endocrine receptors. They differ in metabolism, cell proliferation, protein synthesis, and communication between cells. The combined action of mutations, as well as changes in copy number, define the type of BC, while alterations in epigenetic regulation primarily initiate the development of cancer. BC patients develop drug resistance, recurrence, or therapy failure. The high mortality of BC patients is mainly due to aggressive nature, heterogeneity, metastasis, drug resistance, and recurrence as well as late diagnosis.
Breast tumors consist of cancer cells, surrounding stromal cells, and blood cells in the tumor microenvironment (TME), which are critical for cancer progression and metastasis. For example, suppressor immune cells, soluble factors, and remodeled extracellular matrix (ECM) collectively hamper the anti-tumor immunity but help metastasis. Stromal cells with altered molecular mechanisms as well as abnormal signaling pathways and their interplay with other components of the TME are associated with poor prognosis of BC. Additionally, the ECM can induce changes in biochemical and molecular mechanisms. Furthermore, the molecular signature of the stroma-ECM influences BC progression as well as impacts the drug resistance cancer phenotypes towards hormone-based as well as cytotoxic based therapeutics. Similarly, the cancer-associated stroma (CAS) overexpresses genes encoding ECM, cell cycle-related proteins, matrix metalloproteinases (MMPs) (MMP-2, -11 and -14), and mitochondrial ribosomal proteins during the change to invasive phenotype from pre-invasive phenotype. CAS also correlates with enhanced expression of genes related to immune response. The molecular mechanisms promoting obesity-associated changes in the TME support BC growth by altering functions of adipose tissue, inducing adipocyte demise, and imposing low-grade chronic inflammation. The inflamed TME allows remodeling and infiltration of immune cells and stimulates protumor after-effects to sustain irreversible metastatic progression.
Tumor angiogenesis is a hallmark of solid tumors and an alternative target of metastatic BC. Metastatic breast tumors create unusual vascularization around the tumor by secreting abnormal levels of proangiogenic factors. The vascular network in tumors is highly disorganized and permeable. The abnormal vascularization leads to the development of poorly perfused tumors in the hypoxic TME. This hypoxic environment selects highly invasive and aggressive cancer cells with the ability to escape from tumor-destroying immune cells for metastasis. Furthermore, vascular endothelial growth factor (VEGF) increases angiogenesis by suppressing immunity. In addition, abnormal perfusion decreases the efficacy of chemotherapy and radiation therapy. Apart from cancer cells, tumor-associated leukocytes and stromal cells also promote tumor angiogenesis by secreting extracellular proteases, chemokines, and cytokines as well as exosomes.
Given the complex biology of BC, novel personalized therapeutic strategies that address its diverse pathophysiologies are needed to improve clinical outcomes. Marine sources offer tremendous potential for the detection and advancement of new therapeutic regimens that can assist in BC treatment. Since 1980, advances in biotechnology have enabled new avenues of research exploring marine organisms and their therapeutic potential for novel drug development. This research is dynamic and utilizes advanced technological tools, and has led to an increased interest in exploiting marine microbial, crustacean, and natural fish product scaffolds for rational drug discovery. Marine bioactive compounds represent an accessible source of chemical entities, novel drugs as well as drug leads. They are the basis for nearly 80% of the chemotherapeutics approved by the United States Food and Drug Administration (FDA), and more than half of all drugs. Marine compounds are currently used for the treatment of 87% of diseases, including cancer as they can induce cytotoxicity in cancer cells by targeting mediators of oncogenic transduction pathways or by inhibiting the growth of cancer cells[6,7]. Recent advances in technology and research focusing on marine compounds have allowed the discovery of novel anticancer agents, which are currently undergoing clinical trials.
In the present review, we describe advances in the biology of breast neoplasia, including cellular and molecular biology and heterogeneity as well as epidemiology. Furthermore, we summarize recent knowledge of BC pathophysiology, including the role of TME components in metastasis, angiogenesis, and drug resistance. We then provide an up-to-date review of anticancer compounds originating from marine microorganisms, crustaceans, and fishes and their synergistic effect on anticancer drugs. Finally, we present a summary of the pathophysiology of BC and delineate future directions in the development of marine-based therapeutics for BC.
The biology of BC encompasses a unique signature of histopathology, cellular and molecular heterogeneity and responses, which allows a deeper understanding of BC pathophysiology. The biology of breast tumors in women varies with age. BC in younger women is highly complex and accounts for 15% of all BC subtypes in developing countries. Breast tumors in younger women are classified as high-frequency subtypes with unique signatures of histopathology, genetics, molecular biology, and genomics. Substantial literature validates the function of patient immunosurveillance in affecting response to treatment in some subtypes of BC like triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)+, but its role in estrogen receptor (ER)+ remains unclear because it is less immunogenic, highlighting the need for in-depth clinical studies to improving management strategies in ER+ BC.
AGE SIGNATURE OF BC PATIENTS
BC in younger women exhibits differential gene expression, definite genomic signs, and elevated genetic susceptibility, compared to aged females with BC. In addition, differences in breast stroma, changes in the breast during pregnancy or breastfeeding contribute to the difference in the biology of tumors in younger women. Furthermore, BCs in younger women are multicentric, grade 3, triple-negative, and have a high proliferative index, Ki-67. Furthermore, radiation treatment following BCS can decrease local recurrence from 19.5% to 10.2% in younger BC patients. Clinical investigations evaluating five years of endocrine therapy in TEXT and SOFT trials and extended therapy with tamoxifen in ATTom and ATLAS trials suggest that adjuvant endocrine therapy is an effective treatment for younger BC patients.
BCs in adolescents account for 5.6% of all invasive BC and are likely to be driven by genes responsible for familial cancer predisposition, which cause larger tumors with distinct metastasis. These patients need a multidisciplinary approach of care and treatment regimens to minimize premature menopause, as well as osteoporosis and sexual health. In aged women, BCs found at an initial stage are treatable and have prolonged disease-free survival. Furthermore, adjuvant chemotherapy, radiation or endocrine therapy can reduce the danger of BC recurrence and improve survival. Population-based studies conducted in Asia have recognized that adjuvant modalities, including endocrine and chemotherapy regimens, have significantly improved the overall survival of older women with BC, thus illustrating the beneficial role of clinical studies in ameliorating patient outcomes.
CELLULAR AND MOLECULAR BIOLOGY OF BC
The role of pathological examination in predicting etiology, pathogenesis, and clinicopathological correlations of BCs is the gold standard. Despite many biochemical and histochemical biomarkers, ER, progesterone receptor (PR), and HER-2 are the vital components of clinical examination. Initially, these markers were used for the prognosis of BCs, but also for prediction of treatment outcome. However, high throughput experimentation shows molecular heterogeneity in histologically similar subtypes. For example, high throughput data has facilitated the classification of invasive ductal carcinoma into four categories such as luminal, HER2 amplification type, basal-like and normal breast-like. Among the subtypes, 75% of BCs belong to the luminal type, which exhibits highly complex endocrine resistance due to genetic and epigenetic mechanisms. Epigenetic changes in receptors or their signaling pathways, such as the pattern of DNA methylation, histone modifications, and altered expression of miRNAs, are heritable and reversible in luminal BCs. Lobular carcinoma of invasive (ILC) type of BC accounts for 5%-15% of ductal carcinoma of invasive type. This subtype shows an endocrine response but responds poorly to chemotherapy. Some studies suggest that systemic therapy might be useful for patients with ILC.
Genomic analysis has identified seven BC epitypes (ET1 to ET7). One subtype is characterized by BRCA1 mutations and is linked to basal-like tumors, while another subtype has a complex genome with several additional amplifications such as ERBB2 amplification. A third subtype exhibits a normal epithelial cell-like methylation profile. In contrast, the remaining four epigenetic subtypes look like luminal BCs but differ in genomic instability, promoter, and global hypermethylation as well as the rate of proliferation. Furthermore, high throughput studies have uncovered an interaction between genetic and epigenetic alterations among BC subtypes. The diverse and complex biology of these various BC subtypes highlights the need for personalized targeted therapies that address the specificities of each subtype to enhance patient outcomes. In an effort to identify new biomarkers of each subtype, a microarray study by Zheng et al found differentially expressed genes associated with immune response, cell differentiation, and cell adhesion in various BC types. The genes engage in a protein-protein network with EGFR and spleen-associated tyrosine kinase, which are critical for BC metastasis, and could thus serve as promising novel biomarkers that could improve early BC diagnosis.
CELLULAR AND MOLECULAR HETEROGENEITY OF BC
As the previous section shows, breast tumor consists of genetically, pathologically, and clinically distinct subtypes. Based on the characteristics of histopathology, BC can be classified into three subtypes, including BCs positive for ER/PR, TNBC, and amplified with HER2. TNBCs account for 15% of all BCs, enriched with heterogeneity in terms of BRCA1/2 mutations, expression of androgen receptor (AR) along with rare genomic changes, and a high degree of lymphocyte infiltration. Furthermore, gene expression studies have demonstrated six clinically distinct subsets of TNBC, counting basal-like-1 and -2, immunomodulatory, mesenchymal, luminal AR and mesenchymal stem-like. Breast tumors display hierarchical heterogeneity due to the presence of a high degree of cell plasticity elicited by activated oncogenes, which allows the cells to differentiate into diverse cell types. Also, the differentiation of tumor-initiating cells or stem cells, such as the CD44high/+/CD24low subtypes, in breast tumors underlies tumor heterogeneity and the emergence of aggressive and resistant neoplastic niches.
A BC subclone carrying mutations in AKT, FGFR, PIK3CA, and TP53 and increased chemoresistance, invasiveness, and metastatic ability has been characterized using whole genome and targeted genome sequencing. Single-cell technology has identified a unique claudin-low subclone displaying an epithelial stem cell phenotype and high resistance to chemotherapy. Additionally, a change in the copy number can cause intratumor heterogeneity in BC. For example, HER2 copy numbers can vary in different BC patients. The accumulation of copy number variations due to complex genomic rearrangements or bursts of chromosome changes can induce the development of metastable, pseudodiploid or chromosomic subpopulations in TNBC. Copy number changes are also responsible for the emergence of immune suppressive phenotypes in some T-and B-lymphocytes as well as M2 macrophages.
Molecular heterogeneity in ER has been described in estrogen and androgen hormone responsive BCs, which differ in distant recurrence risk and disease-free survival. Mutational analysis uncovered ER+/PR- BC subpopulations enriched with mutations in TP53, GATA3, CDH1, HER2, and BRAF. Whole exome sequencing studies also reported heterogeneity in ER+/HER2- BCs, which differ in mutational alleles in TP53, CDH1, MYC and have poor overall survival. As these studies show, cellular and molecular heterogeneity pose great challenges in treating metastatic BCs and overcoming drug resistance.
EPIDEMIOLOGY OF BC
Epidemiological investigations have established unmodifiable risk factors such as race, family history of BC, genetic makeup and ethnicity, as well as variable factors such as consumption of alcohol, high-fat diet, female reproductive factors, hormone therapy, obesity as BC causative factors. Additionally, menarche at a younger age, pregnancy at a late age, parity, and nulliparity can also influence BC risk via by affecting sex hormones. Genetic variants and gene mutations in proteins tangled in DNA repair have been implicated as additional risk promoters in BC. Molecular and genetic studies have identified high-risk BC patients with mutations in BRCA1 and BRCA2, along with moderate change of BC-susceptibility genes including PTEN and TP53. Furthermore, GWAS have established the combination of genetic weakness loci, reproductive risk factors, the interaction of gene-environment with obesity and lifestyle as a potential risk factor. Additionally, gene-environment interaction studies have identified BC subtypes in high-risk women. Physical activity can enhance anti-tumor immunity in BC patients by increasing cytotoxic monocytes, natural killer (NK) cells, and cytokines. Recent technological advances have thus allowed an improved characterization of the various BC subtypes and their molecular and genetic underpinnings, which can enable enhanced detection strategies.
PATHOPHYSIOLOGY OF BC
The current understanding of the pathophysiology of the breast TME is that the aggressive and metastatic phenotypes arise through a series of molecular alterations at the cellular and molecular level. Advanced studies have also elucidated the role of sustained angiogenesis in the pathophysiology of TME and the involvement of CSCs and redox biology in drug resistance in BC. The following sections explore the role of the TME in the development and progression of breast tumors.
TME components in BC metastasis
Metastasis is the last step of BC progression and is a common cause of BC mortality. Recent studies show that the components of the TME, including immune suppressive cells, soluble factors, and remodeled ECM, can reciprocally communicate with each other to promote BC metastasis (Figure 1). The breast TME is characterized by unusual signaling pathways and characteristic molecular changes. Tumor associated stomal cell interactions with BC cells promote metastasis through the induction of cytokine (CXCL8) production, which activates the expression of notch1 via tumor necrosis factor (TNF) α-induced p65 activation. Cancer-associated fibroblasts (CAFs) are the most prominent stromal cells of the breast TME and accelerate metastasis by associating with other TME cells. Zhou et al reported that CAFs promote lymph node metastasis of TNBC cells by interacting with tumor-associated macrophages (TAMs). This study also demonstrated that activated CAFs can increase lymphatic metastasis by increasing the intrusion of polarized macrophages in TNBC patients. CAFs promoted lung metastasis of TNBC cells in the homograft tumor model by activating transforming growth factor (TGF) β, thus indicating their key role in BC progression.
Figure 1 Role of tumor microenvironment components in promoting breast cancer metastasis.
Breast tumor microenvironment is typified with different types of components with typical cellular and molecular functions. Tumor associated stromal cells promote metastasis through the induction of cytokine (CXCL8) production by activating the expression of notch1 via TNFα-induced p65 activation. Cancer-associated fibroblasts (CAFs) accelerate lymph node metastasis of triple-negative breast cancer (TNBC) cells by increasing the intrusion of polarized macrophages in TNBC patients. Tumor associated macrophages promote bone metastasis by secreting interleukin 12. CAFs promoted lung metastasis of TNBC cells in the homograft tumor model by activating transforming growth factor β. Cancer associated neutrophils mediates metastasis by leukotrienes. Neutrophils enhance metastatic ability of circulating breast cancer (BC) cells. Notch signaling promotes local invasion of BC cells. Wnt signaling modulates metastasis of BC cells to the lung. TAM: Tumor-associated macrophage; CAF: Cancer-associated fibroblast.
Neutrophils can also accelerate BC metastasis. Coffelt et al reported that neutrophils are expanded and polarized by interleukin (IL) 17 from γδT-cells of breast tumor in mice. The polarized neutrophils promote metastasis by suppressing CD8+ cytotoxic T cells. IL-17 neutralization using specific antibodies reduced the lung metastasis of BC cells by decreasing the T-cell suppressive neutrophils. Another study reported that neutrophils can also mediate BC metastasis through leukotrienes. This study observed that blocking leukotriene synthesizing enzyme 5-lipooxygenase can reduce metastasis by abrogating the prometastatic activity of neutrophils. Additionally, neutrophils can increase the metastatic ability of BC cells by eliciting cell cycle progression via modulating the expression of cytokine receptors and genes associated with cell-cell junctions. Notch signaling also promotes local invasion of BC cells. Furthermore, the Wnt signaling component LGR4 (the fourth member of the leucine-rich repeat-containing GPCR family) is over expressed in BC stem cells (BCSC) and can modulate the metastasis of BC cells to the lung by promoting epithelial to mesenchymal transition (EMT) via increasing the expression of N-cadherin and transcription factor snail and decreasing the expression of E-cadherin. Therapeutic strategies that target and reprogram the TME are thus required to improve treatment outcomes in BC patients.
TME components in BC angiogenesis
In the TME, angiogenesis is modulated by innate immune cells and other communicators (Figure 2), including neutrophils, macrophages, dendritic cells, myeloid-derived cells, γδTcells, mast cells, and NK cells. Lin et al reported that TAMs help angiogenesis after infiltrating into the breast TME. This study correlated the expression of CCL18, CD34, and microvascular density by double immuno-histochemical staining of breast tumor tissues. It also demonstrated the induction of angiogenesis by chemokine, CCL18 in the coculture of TAMs, and endothelial cells. Additionally, the study reported that blocking of CCL18 putative receptor (PITPNM3) inhibited CCL18-promoted migration of endothelial cells as well as tube formation. In contrast, the treatment of endothelial cells with CCL18 stimulated the transition of endothelial cells to mesenchymal cells by activating the Akt/GSK-3β/Snail and ERK (extracellular regulated protein kinases) signaling. In the TME, TAMs induced angiogenesis by remodeling ECM for promoting invasion and BC cell modeling into stem cells for evading host immunity as well as recruiting immune-suppressive immune cells. This study indicates that TAMs can induce angiogenesis and promote the progression of BC.
Figure 2 Modulation of angiogenesis by innate immune cells and other communicators in breast tumor microenvironment.
In breast tumor microenvironment, innate immune cells and other communicators modulate angiogenesis. Tumor-associated macrophages promote angiogenesis by increasing the expression of CCL18, CD34, and microvascular density and assisting breast cancer cell modeling into stem cells for recruitment of immune-suppressive cells. Cancer-associated fibroblasts promote tumor angiogenesis by enhancing the expression of interleukin (IL) 6, IL-8, IL-11 and IL-15 as well as by changing the balance between pro-and anti-angiogenic factors via hypoxia-induced angiogenesis regulator. Tumor-derived exosomal Annexin II induce angiogenesis by recruiting macrophages to secrete IL-6 and tumor necrosis factor-α by activating p38MAPK, nuclear factor-κappa beta, and STAT3 signaling pathways. Exosomal miRNAs contribute to the development of tumor angiogenesis by enhancing the vasculature remodeling genes, Ephrin A3 and PTP1B. TAM: Tumor-associated macrophage; CAF: Cancer-associated fibroblast; HAIR: Hypoxia-induced angiogenesis regulator; NF-κβ: Nuclear factor-κappa beta; TNF: Tumor necrosis factor; IL: Interleukin; BC: Breast cancer.
Similar to TAMs, CAFs promote tumor angiogenesis by various mechanisms. Du et al demonstrated that miRNA-205/YAP1 signaling induces tumor formation as well as the sprouting of endothelial cells by promoting the transformation of normal fibroblasts into CAFs via enhancing the expression of IL11 and IL15. However, blocking of miRNA-205 in CAFs inhibited angiogenesis. Additionally, the study reported that CAFs release IL11 and 15 by stimulating STAT3 signaling in endothelial cells. However, blocking of IL11 and 15 halted CAF-induced angiogenesis as well as BC metastasis by inactivating STAT3 signaling, thus highlighting its therapeutic potential in BC. Furthermore, Eiro et al reported that CAFs can enhance the levels of invasion and angiogenesis-associated genes in BC. The study demonstrated that CAFs derived from MMP11 positive stromal mononuclear inflammatory cells increased the transcript levels of IL-6 and -8 in BC cells in the co-culture model. However, in co-culture of hypoxic CAFs and endothelial cells, CAFs induced abnormal blood vessels formation by changing the balance between anti- and pro-angiogenic factors. This study also revealed that hypoxia altered the expression of hypoxia-induced angiogenesis regulator (HAIR) in CAFs. Furthermore, knockdown of HAIR inhibited CAF-induced migration of endothelial cells by reducing the release of VEGF as well as inhibiting VEGF/VEGFR signaling. These various studies show that CAFs can strongly influence BC development, suggesting that therapeutic strategies that target CAFs in the TME could improve therapeutic responses in BC patients.
Tumor-derived exosomes have emerged as key mediators of tumor-induced angiogenesis. Annexin II (Anx II) is one of the most highly expressed exosomal proteins associated with BC pathogenesis. The exosomal Anx II (Exo-AnxII) reshapes the environment for supporting metastasis, including promoting tPA-mediated angiogenesis. This study reported that Exo-Anx II induces macrophages to secrete IL6 and TNF-α by activating p38 MAPK (mitogen-activated protein kinase), nuclear factor-κappa beta (NF-κB), and STAT3 signaling pathways. Also, exosomal miRNAs from hypoxic tumor cells contribute to the development of tumor angiogenesis. They promote angiogenesis by enhancing the vasculature remodeling genes, including Ephrin A3 and PTP1B, via transferring miRNA-210 to adjacent tumor cells in TME. Exosomes orchestrate angiogenesis for BC metastasis after activation by Notch signaling. The interaction of aspartate β-hydroxylase (ASPH) with Notch signaling components promotes the synthesis and release of exosomes in murine BC models. Exosomes from CXCR4 overexpressing BC cells enhance the expression of stemness-related genes in recipient cells and increase their proliferative, migratory, and invasive ability. In contrast, exosomes from mesenchymal stem cells can reduce angiogenesis in BC by decreasing the VEGF expression via targeting miRNA-16. These studies support the role of exosomes in the modulation of angiogenesis in BC and highlight their importance as novel potentials diagnostic and therapeutic tools in BC.
TME components in drug resistance of BC
In BC, drug resistance and recurrence are mediated by BCSC as well as redox molecules (Figure 3). A fine orchestration between BCSC and TME cells is involved in the process of drug resistance. This interaction promotes drug resistance by upregulating BC resistance protein (BCRP), which mediates the drug efflux mechanism in BC cells. Stem cells from bone marrow, adipose tissue, and fibroblasts also enhance the metastatic potential of BC cells by activating developmental pathways via secreting chemokines and cytokines. Wnt signaling of BCSC along with glutathione overexpressing genes mediates resistance. These mechanisms can reshape the TME leading to increased drug evasion and survival, thus challenging the success of current therapeutic regimens.
Figure 3 Cancer stem cell and redox mediated drug resistance in breast cancer
. In breast tumor microenvironment (TME), a fine orchestration between breast cancer (BC) stem cells (BCSC) and TME cells promotes drug resistance. BCSC promote drug resistance by overexpressing BC resistance protein, which mediates the drug efflux mechanism in BC cells. Stem cells derived from bone marrow, adipose tissue, and fibroblast enhances the drug resistance by activating developmental pathways via secreting chemokines and cytokines. Wnt signaling of BCSC along with glutathione overexpressing genes mediates resistance. Hypoxic TME promotes drug resistance by remodeling of cells from a low reactive oxygen species (ROS) mesenchymal state to a high ROS epithelial state. High ROS from cancer cells induces the production of chemokines to infiltrate monocytes into TME and activates macrophages to promote drug resistance. ROS also induces drug resistance by promoting the immunosuppressive phenotype of tumor-associated macrophages via enhancing the expression of programmed death ligand-1 via NF-κB (nuclear factor-κappa beta) signaling. Multinucleated cells promote drug resistance by increasing the secretion of vascular endothelial growth factor and macrophage migration inhibitory factor (MIF) via RAS/MAPK pathway-dependent hypoxia-inducible factor-1α. Macrophage derived ROS induces drug resistance by increasing transforming growth factor 1β expression via secreting pro-inflammatory cytokines interleukin (IL)-1β and IL-6. ROS also facilitates drug resistance by inducing MIF via promoting phosphorylation of ERK. via activating TLR4 (toll-like receptor 4) signaling. TAM: Tumor-associated macrophage; BC: Breast cancer; ROS: Reactive oxygen species; TGF: Transforming growth factor; IL: Interleukin; TME: Tumor microenvironment; MIF: Macrophage migration inhibitory factor; TLR: Toll-like receptor; BCSC: Breast cancer stem cell.
Additionally, emerging scenarios have recognized that redox signals promote TME mediated drug resistance in BC. Redox mechanisms orchestrate pathophysiology of BC to promote abnormal proliferation, metastasis, and drug resistance through reactive oxygen species (ROS) signals. The hypoxic condition in the TME promotes drug resistance by inducing the remodeling of cells from a low ROS mesenchymal state to a high ROS epithelial state. Cancer cells with high ROS induce drug resistance by producing chemokines that elicit the infiltration of monocytes into the TME and activate macrophages to promote angiogenesis. ROS also induces drug resistance by promoting the immunosuppressive phenotype of TAMs, which release immuno-suppressive chemokines by increasing the levels of programmed death ligand-1 (PD-L1) via NF-κB signaling. In the breast TME, multinucleated cells promote drug resistance by increasing VEGF secretion and macrophage migration inhibitory factor (MIF) via RAS/MAPK pathway-dependent hypoxia-inducible factor (HIF)-1α. Macrophages induce TGF-1β expression in cancer cells by secreting IL-1β and IL-6. These cytokines promote EMT and migration of tumor cells by activating pCREB signaling via ROS. ROS facilitates drug resistance in metastatic cells by inducing MIF via promoting phosphorylation of ERK, which promotes the release of high-mobility group box 1 (HMGB1) into the cytosol from the nucleus by inducing caveolin-1 phosphorylation. The released HMGB1 then phosphorylates NF-κB via activating TLR4 (toll-like receptor 4) signaling. The activated NF-κB activates MMP2 and induces transcription of Snail and Twist. This MIF-mediated HMGB1 signaling regulates the CD11b+ immune cell recruitment in the breast TME and promotes drug resistance. As these various studies show, the TME plays a key role in BC development and metastasis. Hence, novel therapeutic regimens that target the various components of the TME to overcome resistance mechanisms could unleash the native immune system against BCs and improve therapeutic outcomes.
LONG NON-CODING RNAS IN THE PATHOPHYSIOLOGY OF BC
Recently, long non-coding RNAs (lncRNAs) have been reported to mediate pathophysiological developments such as metastasis as well as immune suppression within the TME (Figure 4). Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a lncRNAs enriched in the nucleus and helps cancer growth and progression by regulating gene expression and post-translational modifications. In TNBC cells, MALAT1 drives tumor progression and metastasis. The expression levels are correlated with reduced disease-free survival in both HER2 and TNBC patients, who are negative for ER and lymph node. MALAT1interacts with ER, and its increased expression levels correlate with ER and PR positive status in BCs with prognostic significance (cut-off value 75%) associated with relapse. It also promotes invasion and migration of TNBCs by targeting tumor suppressor miRNA-129-5p, but its silencing induced cell cycle arrest at G0/G1phage. Hence, MALAT1 could be a potential diagnostic tool for BC (Figure 4).
Figure 4 Role of long non-coding RNAs in the pathophysiology of breast cancer.
Long non-coding RNAs are reported to mediate pathophysiological developments such as metastasis as well as immune suppression within the tumor microenvironment. Metastasis-associated lung adenocarcinoma transcript 1 promotes growth and metastasis by controlling gene expression and post-translational modifications, invasion and migration by targeting tumor suppressor miRNA-129-5p, metastasis by transcriptionally regulating disruptor of telomeric silencing 1-like and promoting the interaction of hypoxia-inducible factor-2α. HOTAIR (HOX antisense intergenic RNA) increases invasiveness and metastasis by enhancing the expression of polycomb repressive complex 2 and altering the epigenome by histone H3 lysine 27 methylation, enhancing cell migration and invasiveness and inhibiting apoptosis through targeting high mobility AT-hook 2 via miRNA-20a-5p. MEG3 reduced angiogenesis by decreasing the expression of proangiogenic molecules as well as blocking Akt signaling. NKILA [nuclear factor-κappa beta (NF-κB) interacting lncRNA] negatively regulates tumor angiogenesis by decreasing the interleukin-dependent expression of vascular endothelial growth factor (VEGF)-A and VEGF-R through inhibiting NF-κB signaling and promotes antitumor immunity by inducing immune evasion of tumor cells via sensitizing T-cells through activation-induced cell death mechanism. LINC00968 inhibits capillary formation by downregulating miRNA-423-5p mediated PROX1. LINC01133 promotes stem cell phenotypes by triggering miRNA-199a dependent FOXP2 signaling via modulation of Kruppel-like factor 4. Silencing of lncRNA-21 in tumor-associated macrophages induced apoptosis and reduced cell migration and invasion. LINK-A promotes antitumor immunity by inducing loss of antigenicity through PIP3 and inhibitory G-protein coupled receptor pathway as well as attenuating protein kinase A-dependent phosphorylation of E3 ubiquitin ligase TRIM71 and degradation of antigen peptide loading complex in triple-negative breast cancer. MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; DOT1L: Disruptor of telomeric silencing 1-like; HIF: Hypoxia-inducible factor; HOTAIR: HOX antisense intergenic RNA; PRC2: Polycomb repressive complex 2; HMGA2: High mobility AT-hook 2; TNBC: Triple-negative breast cancer; IL: Interleukin; VEGF: Vascular endothelial growth factor.
Silencing of MALAT1 reduced cancer growth and progression by increasing cell adhesion and decreasing migration of cancer cells in mouse mammary carcinoma model via altering the expression pattern of genes implicated in differentiation and protumorigenic signaling pathways. The expression patterns of MALAT1 and transcription factor BACH1 were substantially associated with TNM stage, metastatic ability, and pathological stage as well as the survival of patients. MALAT1 can possibly promote metastasis in association with ZEB2 by transcriptionally regulating disruptor of telomeric silencing 1-like in BC. Furthermore, hypoxia induces MALAT1, which also enhances the metastasis of BCs by promoting the interaction of HIF-2α with the MALAT1 gene between the promoter region and putative enhancer-3 as well as chromatin interactions with putative enhancer-7. In contrast, Kim et al reported that overexpression of MALAT1 can reduce metastasis of BC cells in the xenograft model by hindering the interaction of TEAD with YAP via transcriptional inactivation. However, the silencing of MALAT1 enhances the metastatic ability of BC cells.
Another important lncRNA that promotes metastasis of BCs by reprogramming chromatin state is HOX antisense intergenic RNA (HOTAIR). It is highly expressed in both primary as well as metastatic breast tumors. Its expression is strongly correlated with lymph node metastasis and the expression of the AR. Mechanistically, HOTAIR upregulation using overexpressing plasmid enhanced the expression of polycomb repressive complex 2 (PRC2) and altered the epigenome by histone H3 lysine 27 methylation. It also enhanced invasiveness and metastasis in BCs, while its silencing inhibited invasiveness in PRC2 overexpressing BCs. HOTAIR can also promote progression by increasing migration and invasiveness and inhibiting apoptosis through targeting high mobility AT-hook 2 (HMGA2) via miRNA-20a-5p in BC cells.
The overexpression of MEG3 reduced angiogenesis in BC by reducing the capillary formation of endothelial cells via decreasing the expression of proangiogenic molecules as well as blocking Akt signaling. However, overexpression of lnc RNA NKILA (NF-κB interacting lncRNA) significantly reduced tumor angiogenesis by reducing the IL-dependent VEGF-A and VEGF-R expressions through inhibiting NF-κB signaling and IkBα phosphorylation and nuclear translocation. Recently, Sun et al reported that overexpression of lncRNA (LINC00968) reduced capillary formation by downregulating miRNA-423-5p mediated PROX1 in BC cells. Another lnRNA, LINC01133 promoted stem cell phenotypes in TNBC cells by triggering miRNA-199a dependent FOXP2 signaling via modulation of Kruppel-like factor 4. TME induced stemness in BC cells by silencing lncRNA-HAL through chromatin level and transcriptional regulation.
Additionally, lncRNAs can regulate tumor immunity through various mechanisms. Huang et al reported that NKILA promotes antitumor immunity by inducing immune evasion of tumor cells via sensitizing T-cells through activation-induced cell death mechanism. Silencing of lncRNA-21 in TAMs induced apoptosis in BC cells and reduced metastasis. In contrast, lncRNA (LINK-A) promotes antitumor immunity by inducing loss of antigenicity through PIP3 and IGPCR pathway in TNBC. Hence, lncRNAs can modulate metastasis at different molecular levels, including epigenetic modification and multiple signaling pathways. Future studies could lead to the development of clinical applications based on lncRNAs as potential diagnostic biomarkers or drug targets.
As the previous sections show, the complex pathophysiology poses a challenge to the development of effective therapeutic regimens. Novel personalized strategies that target the BC TME are required to improve clinical responses. Natural compounds (e.g., cytarabine, eribulin mesylate) from marine organisms have been approved by the FDA for cancer treatment and could represent valuable clinical modalities for BC. Several marine compounds with antineoplastic activity are currently undergoing different phases of evaluation in clinical trials (e.g., plinabulin). Additionally, the anticancer activity of more than 1500 marine compounds has been evaluated using in vivo models while the activity of 10000 compounds has been tested using in vitro models. Marine compounds malformin A (cyclic pentapeptide), kuanoniamine D (pyridoacridine alkaloid), hymenialdisine (C11–N5 alkaloid), and gallic acid (GA, phenolic acid) exert potentially high anticancer activity against MCF-7 BC cells by inducing apoptosis and promoting nuclear fragmentation, membrane protrusion, blebbing and chromatin segregation. The following paragraphs will examine some of the best-studied marine compounds and explore their relevance to BC treatment.
Marine compounds with potential anti-BC activity from microorganisms and algae
Marine compounds from microorganisms have potential anticancer activity (Table 1). For example, GA can stimulate apoptosis by changing p53, Mcl, and p21 expression. GA can also stimulate cell cycle arrest in BC cells by altering the cyclin-dependent kinases (CDKs) expression. Mechanistically, MAP38 kinase is intricated in GA-stimulated cell cycle arrest and apoptosis via downregulating cyclin Da/CDK4 and cyclin E/CDK2. However, a combination of GA with curcumin stimulated apoptosis in BC cells by overexpressing the expression of Bax as well as activating caspase 3 and poly (ADP ribose) polymerase (PARP) and decreasing Bcl2 along with arresting at sub-G1 phase. In addition, a nanocomposite of iron oxide magnetite nanoparticles (NPs) and polyethylene glycol (PEG) enhanced the anticancer activity of GA. Moreover, GA conjugated Gold NPs suppressed the metastasis of MDA-MB cells by blocking EGF dependent MMP-9 expression via suppressing stabilization of p300 as well as activating NF-κB/c-Jun pathway. However, overexpression of MEK1 and Akt reduced the inhibitory activity of GA on the EGF-dependent upregulation of MMP-9. Crambescidin 800 is a heteropenta cyclic guanidine alkaloid. Crambescidin 800 stimulated arrest at the G2M phase by decreasing the cyclin D1, CDK-4, and -6 expression in TNBC cells via modulating the Akt/NF-κB/MAPK pathway and thus warrants further clinical investigation.
Table 1 Marine compounds with potential anticancer activity against breast cancer from microorganisms and algae.
Mechanism of action
Gallic acid (GA)
(1) Altered the expression of P53, Mcl and p21 as well as cell cycle regulators; and (2) MAP38 kinase involved in GA induced cell cycle arrest and apoptosis via downregulating cyclin Da/CDK4 and cyclin E/CDK2
(1) Abrogated elastase-dependent migration of highly metastatic TNBC cells; and (2) Inhibited the activity of elastase and the migration of TNBC cells by targeting the expression of ICAM-1 via inhibiting the NF-κB pathway
Inhibited migration by inhibiting cell proliferation, inducing cell arrest via DNA damage. Mechanistically, CLP induced cell cycle arrest by blocking the expression of cyclin C, CDK4, PAK, RAC1, and p27kiP1 via targeting CD151 and EGFR signaling axis in TNBC cells
Reduced the CCL27 and stimulated proliferation and progression of metastatic BC cells by targeting serine protease kallikrein 7 (KLK7). This study reported that brintonamide D targeted KLK7 by modulating CCR10, the receptor of CCL27 in BC cells
(1) Induced apoptosis by increasing sub-G1 cell population, fragmentation of DNA via inhibiting FGF-mediated phosphorylation of Akt, FoxO3a and GSK3β; (2) And reduced tumor growth by promoting translocation of FoxO3a via downregulating MAPK and Akt kinase in the xenograft model
Reduced cell viability by halting at the G2M phase and stimulating apoptosis through activation of caspase-3 and -8 as well as PARP. In addition, it also induced DNA damage by generating ROS via stimulating oxidative stress
(1) Induced apoptosis by inhibiting ER Ca2+ -ATPase (SERCA) activity via releasing Ca2+ from ER and inducing DNA fragmentation; (2) Reduced the Bcl2 expression and enhanced the caspase 8 expression; and (3) Induced cell death in an ER-mediated extrinsic apoptotic pathway
(1) Reduced cell growth by inhibiting proliferation; (2) Induced apoptosis, and autophagy via generating ROS; and (3) Silenced Atg7 with siRNA and blockade of autophagy using bafilomycin A1 synergistically increased the efficacy of hirsutanol A in inducing apoptosis and inhibiting cell proliferation
(1) Induced apoptosis in HER+ve BC cells by reducing the Bcl2 expression and increasing the Bax expression; and (2) Promoted cell death via ROS-dependent extrinsic or intrinsic apoptotic pathways without systemic toxicity in the mouse model
(1) Inhibited cell growth by inducing apoptosis via activation of caspase 3 and PARP and cell cycle arrest via targeting cyclin D1 and CDK6 through blocking the p38/ERK signaling pathway; and (2) Induced autophagy via generating ROS and DNA damage by increasing the expression of H2AX
The polysaccharide EPS11, isolated from marine bacteria, inhibits lung metastasis by inhibiting the cell adhesion protein CD99. It also inhibits cancer cell growth by inducing anoikis via inducing the Akt pathway-dependent expression of βIII-tubulin. The polysaccharide fractions, SWP1, and SWP2 from brown seaweed decreased the proliferation of BC cells by stimulating apoptosis and activating caspase 3/9 and disrupting the mitochondrial membrane via generation of ROS. Carrageenan, a polysaccharide from red algae, inhibited BC cells at 50 μg by inducing apoptosis via promoting condensation of the nucleus and fragmentation of DNA as well as activating caspase 8, an extrinsic apoptotic protein. Exopolysaccharides from marine algae inhibited the growth of BC cells by reducing the cyclin D1 and E transcript levels, while inducing the proliferation of B-cells and decreasing the IL-6 and TNF-1α production in T-cells. Hence this compound displays promising immunomodulatory effects that warrant further investigation.
The marine compound, Ilmycin C, is a cyclic peptide, that inhibits the invasion and migration of BC cells by inducing apoptosis via Bax/Bcl-2 dependent caspases as well as inhibiting MMP-2 and -9 via blocking IL-6 dependent phosphorylation of STAT3. Ilamycin E can also inhibit TNBC growth by inducing apoptosis through activating SR stress and reducing Bcl2 in a CHOP dependent manner. Cyclic depsipeptide, molassamide can abrogate elastase-dependent migration of highly metastatic TNBC cells. It can also inhibit the activity of elastase and the migration of TNBC cells by targeting the expression of ICAM-1 (intercellular adhesion molecule-1) via decreasing NF-κB. Another cyclic depsipeptide, kempopeptin C from marine cyanobacteria can inhibit the invasion and migration of TNBC cells by reducing the cleavage of matriptase substrates CDCP1 (CUB-domain containing protein 1) and sesmoglein-2. However, cyclic dipeptide of leucine and proline (CLP) decreased TNBC cells migration by inhibiting proliferation and inducing G2/M arrest via DNA damage. Mechanistically, CLP induced cell cycle arrest by blocking cyclin C, CDK4, PAK, RAC1, and p27kiP1 expression via targeting CD151 and EGFR signaling axis in TNBC cells. The marine cyclic pentapeptide galaxamide and its analogs elicited apoptosis in BC cells by arresting the G0/G1 phase as well as reducing mitochondrial membrane potential via the generation of ROS. These various studies illustrate the wide ranging molecular and immunomodulatory effects of marine compounds, highlighting their versatility as potential sources of TME modulating molecules with therapeutic benefits.
Brintonamide D is a linear peptide that can reduce CCL27-stimulated proliferation and migration of metastatic BC cells by targeting serine protease kallikrein 7 (KLK7). This study reported that brintonamide D targeted KLK7 by modulating CCR10, the receptor of CCL27 in BC cells. Iturin A, a marine bacterium derived lipopeptide, stimulated apoptosis in BC cells by increasing sub-G1 cell population, fragmentation of DNA via inhibiting FGF-mediated phosphorylation of Akt, FoxO3a and GSK3β. This study also reported that Iturin A reduces tumor growth by promoting translocation of FoxO3a via inactivating MAPK and Akt kinase in the xenograft model. Furthermore, Halilectin-3, a sugar-binding lectin protein from marine sponges, inhibited BC cell proliferation by stimulating the G0/G1 arrest. It also promoted apoptosis by increasing the activity of caspase 9 and autophagy by inducing the expression of the light chain 3. These various marine compounds display promising anti-tumor activity that could be harnessed to target the BC TME in a non-invasive and non-toxic fashion.
The marine terpenoid sinularin can decrease the viability of TNBC cells by halting the the G2/M phase and inducing apoptosis through activation of caspase-3 and -8 and PARP. In addition, it can also induce DNA damage by generating ROS via stimulating oxidative stress. Sipholenol A, a triterpene from marine sponges, reduced the metastatic ability of TNBC cells by inhibiting protein tyrosine kinase 6, a key mediator of growth factor-dependent migration. Agelasine B is a diterpene alkaloid from marine sponges that can stimulate apoptosis in BC cells by inhibiting ER Ca2+ -ATPase (SERCA) activity via releasing Ca2+ from ER and inducing DNA fragmentation. It also reduced Bcl2 expression and increased caspase 8 levels. This study demonstrated that Agelasine B can induce cell death in BC cells through an ER-mediated extrinsic apoptotic pathway. Hirsutanol A, a sesquiterpene from marine fungus, also reduced the growth of BC cells by inhibiting proliferation and stimulating autophagy and apoptosis via generating ROS. Silencing of Atg7 with siRNA and blockade of autophagy using bafilomycin A1 synergistically increased the efficacy of hirsutanol A in inducing apoptosis and inhibiting cell proliferation. This study indicates that hirsutanol A can induces autophagy and programmed cell death (PCD) by enhancing ROS accumulation in BC cells. Dehydrothyrsiferol (DT) is a triterpenoid that promotes apoptosis in BC cells by DNA fragmentation and arrest at S-phase and G2M phase. Sodwanone, a marine triterpene, is highly toxic to BC cells and can inhibit hypoxia-induced HIF-1α. Pseudopterosin, a marine diterpene glycoside, also decreased the production of IL-6, TNF-1α, and MCP-1 (monocyte chemotactic protein-1) in BC cells via blocking p65 and IkB phosphorylation as well as promoting translocation of glucocorticoid receptor from nucleus to cytosol.
Quinazoline, a six-membered nitrogen-containing heterocyclic compound from marine sponge Hyrtios erectus, stimulated apoptosis in HER-positive BC cells by decreasing Bcl2 expression and increasing Bax. This study reported that quinazoline promoted cell death via ROS-dependent extrinsic or intrinsic apoptotic pathways without systemic toxicity in the mouse model. Sharifi et al showed that marine compounds (3β)-Cholest-5-en-3-ol (cholesterol), 2-hexadecanol and hexadecanoic acid from sea pen stimulated cell death in TNBC cells by activating caspase 3 and 8 as well as increasing Bax expression and reducing Bcl 2 levels. Furthermore, a sterol from soft corals inhibited BC cell growth by stimulating apoptosis via activation of caspase 3 and PARP. It also elicited Go/G1 arrest by reducing cyclin D1 and CDK6 and blocking p38/ERK signaling. Furthermore, it induced autophagy via generating ROS and DNA damage through H2AX upregulation. Another marine compound, 4-methyenedioxy-β-nitrostyrene (MNS) also inhibited the migration of TNBC cells by disrupting the focal adhesion complex as well as a network of actin stress fibers via reducing β1 integrin-dependent phosphorylation of FAK (focal adhesion kinase) and paxillin. Yang et al reported that leucine aminopeptidase-3 (LAP-3) can inhibit the growth, invasion and migration of TNBC cells by targeting LAP-3 dependent expression of fascin and MMP-2/9. As these studies illustrate, marine compounds display a wide range of antineoplastic effects that could be exploited to develop novel drug modalities for BC.
Marine compounds with potential anti-BC activity from crustaceans
The crustacean shell is a rich source of chitin. Crab, the major crustacean, is highly recommended for cancer treatment in traditional medicine due to chitin, carotenoids (astaxanthin, AST), lutein, and β-carotene (Table 2). The hydro-alcoholic extract of crab shells can reduce the proliferation of MCF-7 cells by stimulating apoptosis and decreasing nitric oxide production. This study reported that chitosan and its oligosaccharides, AST as well as selenium could be the principle compounds accountable for the anticancer activity of hydro-alcoholic extract of crab. Chitosan from shrimp shell waste reduced the proliferation of MCF-7 cells without affecting normal fibroblasts by stimulating G2/M arrest and apoptosis, decreasing Bcl2 expression and upregulating p53 levels[104,105]. AST from shrimps, a marine crustacean, induced PCD in BC cells via alteration in expression of cyclin D1, Bax, p53, and Bcl2 through arrest at G0/G1 phase. Chondroitin sulfate from shrimps inhibited angiogenesis by reducing tube formation via inhibiting the expression of VEGF. β-carotene stimulated apoptosis in BC cells by inducing the release of cytochrome C, increasing PPAR-γ (peroxisome proliferator-activated receptor gamma), and p21(WAF1/CIP1) expression and decreasing cyclooxygenase-2 expression through ROS generation. These studies suggest that bioactive compounds from marine crustaceans are potential targets of BC.
Table 2 Marine compounds with potential anticancer activity against breast cancer from crustaceans.
Mechanism of action
Hydro-alcoholic extract of crab
Chitosan and Astaxanthin
Reduced proliferation by inducing apoptosis and decreasing nitric oxide production
Marine compounds with potential anti-BC activity from marine fishes
The muscle and live tissues of marine fishes have been described as a source of anticancer compounds (Table 3). Epidemiological studies show that high consumption of fish and seafood in Asian countries correlates with a low prevalence of BC. A meta-analysis studies reported that high consumption of marine fish can reduce the risk of BC due to the presence of n-3 polyunsaturated fatty acids (PUFA) as well as α-linolenic acid. Another epidemiological study reported a positive association between the reduction of invasive BC risk and intake of fatty fish but not with the intake of lean fish. Some in vitro and animal studies also confirmed the inhibitory effect of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and n-3 PUFA from marine fish on BC growth. The intake of fish containing EPA and DHA showed a dose-dependent reduction of BC risk. Two peptides (K092A and K092B) from marine fish stimulated apoptosis in BC cells by altering the cytoskeleton via targeting actin and tubulin, halting at the G2M phase and decreasing mitochondrial activity. A tetrahydroisoquinoline alkaloid, trabectedin from tunicate, induced death receptor-mediated apoptosis by increasing the expression of TNF-related apoptosis-inducing ligand (TRAIL)-R1, -R2, Fas, TNF RI, and FADD (fas-associated protein with death domain) in BC cells. Hence, marine compounds extracted from marine fish can display a wide and divers’ range of anti-cancer effects and warrant further study to exploit their potential therapeutic properties in the context of BC.
Table 3 Marine compounds with potential anticancer activity from marine fishes and invertebrates against breast cancer.
(1) Induced death receptor-mediated apoptosis by increasing the expression of TRAIL-R1, -R2, Fas, TNF RI, and FADD; and (2) Induced mitochondrial-mediated apoptosis by decreasing the of Bcl2 and Bcl-XL expression and increasing the Bax, Bad, cytochrome C and caspase 3 expression via increasing the ROS generation
BC: Breast cancer; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; PUFA: Polyunsaturated fatty acids; TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand; TNF: Tumor necrosis factor; FADD: Fas-associated protein with death domain; ROS: Reactive oxygen species.
Combination of marine compounds and chemotherapeutics
Marine compounds can resensitize resistant BC cells to chemotherapy (Table 4). For instance, marine-derived cyclic peptide, elisidepsin, and cisplatin or paclitaxel showed synergistic toxicity on BC cells by reducing the phosphorylation of Akt and inhibiting the MAPK pathway via targeting ERBB expression. Sipholenol A increased the sensitivity of paclitaxel in BC cells by inhibiting P-glycoprotein (P-gp) and multidrug-resistant associated protein (MRP1). Permethyl ningalin B, resensitized BC cells to paclitaxel by inhibiting drug efflux activity of P-gp and increasing drug accumu-lation. Preclinical studies reported that trabectedin (ET-743) used with a combination of cisplatin or paclitaxel or doxorubicin displayed an additive effect in the preclinical system. Moreover, marine polysaccharides, in combination with cisplatin, synergistically inhibited TNBC cells growth and migration by blocking MMP-2 and MMP-9 expression. Iturin A, combined with docetaxel, substantially sensitized docetaxel-resistant TNBC cells by reducing proliferation via massive arrest at the G1 phase, increasing caspase 3 levels and inhibiting Akt and its downstream signaling pathways. Renieramycin M, a tetrahydroisoquinoline from blue sponges, sensitized MCF-7 cells synergistically to doxorubicin by promoting doxorubicin-induced DNA damage, cell cycle arrest, and apoptosis via downregulating ERBB/PI3K-Akt, integrin, and focal adhesion signaling. Zhang et al demon-strated that marine sulfated polysaccharide in a combination of pH-sensitive doxorubicin releasing nanosystem inhibited growth and progression of BC cells in tumor-bearing mice. Furthermore, papuamine, a marine compound from sponges, inhibited the colony-forming ability of BC cells at a subtoxic concentration by targeting activation of JNK. Hence, marine compounds can resensitize refractory BC cells to chemotherapy and display promising potential as therapeutic companion tools to overcome drug resistance in BC.
Table 4 Marine compounds with potential anticancer activity and chemotherapeutics against breast cancer.
Mechanism of action
With combination of cisplatin or paclitaxel showed synergistic toxicity on BC cells by reducing the phosphorylation of Akt and inhibiting the MAPK pathway via targeting ErbB expression
In combination with docetaxel, substantially sensitized docetaxel-resistant TNBC cells by reducing proliferation via massive arresting at the G1 stage and activating caspase 3 as well as inhibiting Akt and its downstream signaling pathways
Sensitized MCF-7 cells synergistically to doxorubicin by promoting doxorubicin-induced DNA damage, cell cycle arrest, and apoptosis via downregulating ErbB/PI3K-Akt, integrin, and focal adhesion signaling
BC: Breast cancer; MAPK: Mitogen-activated protein kinase; P-gp: P-glycoprotein; MRP: Multidrug-resistant associated protein; MMP: Matrix metalloproteinase; TNBC: Triple-negative breast cancer; DOX: Doxorubicin; JNK: c-Jun N-terminal kinase.
As this in-depth review shows, BC is a highly complex and heterogenous disease and remains one of the major causes of female mortality worldwide. Hence, novel diagnostic tools and drug targets are needed to develop effective management and treatment regimens that overcome chemoresistance and increase survival. The search for novel treatment BC strategies has prompted the clinical investigation of various anticancer compounds extracted from marine microorganisms. As per our detailed survey, marine compounds display promising antineoplastic therapeutic potential for BC. In fact, their enormous genetic diversity supports a wide range of anti-cancer and immunomodulatory mechanisms of action that could be harnessed for BC treatment. Future pharmaceutical development is required to improve the pharmacokinetic properties of these compounds and evaluate their efficacy. Although marine compounds represent a relatively young discipline, their chemical diversity, eco-friendliness and therapeutic properties render them a promising new source of anticancer drugs. The use of novel bioengineering tools will enormously help in improving their production and clinical development for the treatment of BC and other cancers.
Manuscript source: Invited manuscript
Corresponding Author's Membership in Professional Societies: American Association for Cancer Research, No. 229378.
Specialty type: Biochemistry and molecular biology
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S. Genetic and epigenetic aspects of breast cancer progression and therapy.Anticancer Res. 2014;34:1071-1077.
[PubMed] [DOI][Cited in This Article: ]
Schmidt T, van Mackelenbergh M, Wesch D, Mundhenke C. Physical activity influences the immune system of breast cancer patients.J Cancer Res Ther. 2017;13:392-398.
[PubMed] [DOI][Cited in This Article: ]
Parekh A, Das S, Parida S, Das CK, Dutta D, Mallick SK, Wu PH, Kumar BNP, Bharti R, Dey G, Banerjee K, Rajput S, Bharadwaj D, Pal I, Dey KK, Rajesh Y, Jena BC, Biswas A, Banik P, Pradhan AK, Das SK, Das AK, Dhara S, Fisher PB, Wirtz D, Mills GB, Mandal M. Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo.Oncogene. 2018;37:4546-4561.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 31][Cited by in F6Publishing: 19][Article Influence: 10.3][Reference Citation Analysis (0)]
Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.Nat Immunol. 2019;20:835-851.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 101][Cited by in F6Publishing: 64][Article Influence: 50.5][Reference Citation Analysis (0)]
De AK, Muthiyan R, Mondal S, Mahanta N, Bhattacharya D, Ponraj P, Muniswamy K, Kundu A, Kundu MS, Sunder J, Karunakaran D, Bera AK, Roy SD, Malakar D. A Natural Quinazoline Derivative from Marine Sponge Hyrtios erectus Induces Apoptosis of Breast Cancer Cells via ROS Production and Intrinsic or Extrinsic Apoptosis Pathways.Mar Drugs. 2019;17.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 10][Cited by in F6Publishing: 6][Article Influence: 5.0][Reference Citation Analysis (0)]
Engeset D, Alsaker E, Lund E, Welch A, Khaw KT, Clavel-Chapelon F, Thiébaut A, Chajès V, Key TJ, Allen NE, Amiano P, Dorronsoro M, Tjønneland A, Stripp C, Peeters PH, van Gils CH, Chirlaque MD, Nagel G, Linseisen J, Ocké MC, Bueno-de-Mesquita HB, Sacerdote C, Tumino R, Ardanaz E, Sánchez MJ, Panico S, Palli D, Trichopoulou A, Kalapothaki V, Benetou V, Quirós JR, Agudo A, Overvad K, Bjerregaard L, Wirfält E, Schulz M, Boeing H, Slimani N, Riboli E. Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC).Int J Cancer. 2006;119:175-182.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 63][Cited by in F6Publishing: 25][Article Influence: 4.2][Reference Citation Analysis (0)]